Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib.

Jiang C, Tang Y, Lu CA, Shih YT, Yabroff KR, Han X, Hu X

DOI: 10.1093/haschl/qxag208
Published: 2026 Aug
Container: Health affairs scholar
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/haschl/qxag208,
  title = {Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib.},
  author = {Jiang C and Tang Y and Lu CA and Shih YT and Yabroff KR and Han X and Hu X},
  year = {2026},
  journal = {Health affairs scholar},
  doi = {10.1093/haschl/qxag208},
  url = {https://doi.org/10.1093/haschl/qxag208}
}

RIS

TY  - JOUR
TI  - Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib.
AU  - Jiang C
AU  - Tang Y
AU  - Lu CA
AU  - Shih YT
AU  - Yabroff KR
AU  - Han X
AU  - Hu X
PY  - 2026
JO  - Health affairs scholar
DO  - 10.1093/haschl/qxag208
UR  - https://doi.org/10.1093/haschl/qxag208
ER  -

APA

C, J., Y, T., CA, L., YT, S., KR, Y., X, H., & X, H. (2026). Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib.. Health affairs scholar. https://doi.org/10.1093/haschl/qxag208

Source records

pubmed · retrieved 2026-09-25T18:48:51.241Z